复宏汉霖： HLX48获澳洲临床备案填补同类药物市场空白

财中社05-13

　　5月13日，复宏汉霖（02696）发布公告，公司自主研发的注射用HLX48（靶向EGFR和c-MET的抗体偶联药物）用于晚期/转移性实体瘤治疗的1期临床试验已获得相关人类研究伦理委员会的批准，并通过澳大利亚药品管理局的临床试验备案。

　　HLX48是一款靶向c-MET和EGFR的双特异性抗体偶联药物，旨在通过诱导受体介导的内吞作用来实现肿瘤细胞的靶向治疗，并具备良好的安全性。市场上尚无靶向EGFR和c-MET的双特异性抗体偶联药物获得批准，公司在这一领域的开发具有潜在的市场机会。

（文章来源：财中社）

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2635200887?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-05-13 17:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635200887","market":"us","top_or_hot":-1,"title":"复宏汉霖： HLX48获澳洲临床备案 填补同类药物市场空白","media":"财中社","content":"<html><body><div>\n<p><img border=\"0\" height=\"276\" src=\"https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=116.02696&amp;imageType=k&amp;token=28dfeb41d35cc81d84b4664d7c23c49f&amp;at=1\" width=\"578\"/></p><p>　　5月13日，<span><a href=\"https://laohu8.com/S/02696\">复宏汉霖</a></span>（02696）发布公告，公司自主研发的注射用HLX48（靶向EGFR和c-MET的抗体偶联药物）用于晚期/转移性实体瘤治疗的1期临床试验已获得相关人类研究伦理委员会的批准，并通过澳大利亚药品管理局的临床试验备案。</p><p>　　HLX48是一款靶向c-MET和EGFR的双特异性抗体偶联药物，旨在通过诱导受体介导的内吞作用来实现肿瘤细胞的靶向治疗，并具备良好的安全性。市场上尚无靶向EGFR和c-MET的双特异性抗体偶联药物获得批准，公司在这一领域的开发具有潜在的市场机会。</p><p>（文章来源：财中社）</p> </div></body></html>","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>复宏汉霖： HLX48获澳洲临床备案 填补同类药物市场空白</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n复宏汉霖： HLX48获澳洲临床备案 填补同类药物市场空白\n</h2>\n\n<h4 class=\"meta\">\n\n</h4>\n\n</header>\n<article>\n<html><body><div>\n<p><img border=\"0\" height=\"276\" src=\"https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=116.02696&amp;imageType=k&amp;token=28dfeb41d35cc81d84b4664d7c23c49f&amp;at=1\" width=\"578\"/></p><p>　　5月13日，<span><a href=\"https://laohu8.com/S/02696\">复宏汉霖</a></span>（02696）发布公告，公司自主研发的注射用HLX48（靶向EGFR和c-MET的抗体偶联药物）用于晚期/转移性实体瘤治疗的1期临床试验已获得相关人类研究伦理委员会的批准，并通过澳大利亚药品管理局的临床试验备案。</p><p>　　HLX48是一款靶向c-MET和EGFR的双特异性抗体偶联药物，旨在通过诱导受体介导的内吞作用来实现肿瘤细胞的靶向治疗，并具备良好的安全性。市场上尚无靶向EGFR和c-MET的双特异性抗体偶联药物获得批准，公司在这一领域的开发具有潜在的市场机会。</p><p>（文章来源：财中社）</p> </div></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://finance.eastmoney.com/a/202605133736002952.html\">财中社</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000306701.USD","symbol_name":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","start_time":0,"source_url":"http://finance.eastmoney.com/a/202605133736002952.html","article_id":"2635200887","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2635200887","pubTimestamp":1778665080,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"5月13日，复宏汉霖（02696）发布公告，公司自主研发的注射用HLX48（靶向EGFR和c-MET的抗体偶联药物）用于晚期/转移性实体瘤治疗的1期临床试验已获得相关人类研究伦理委员会的批准，并通过澳大利亚药品管理局的临床试验备案。HLX48是一款靶向c-MET和EGFR的双特异性抗体偶联药物，旨在通过诱导受体介导的内吞作用来实现肿瘤细胞的靶向治疗，并具备良好的安全性。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","BK1161":"生物科技","02696":"复宏汉霖","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC"},"translate_title":"Henlius: HLX48 obtained clinical registration in Australia to fill the gap in the similar drug market","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02696":1.5},"content_text":"5月13日，复宏汉霖（02696）发布公告，公司自主研发的注射用HLX48（靶向EGFR和c-MET的抗体偶联药物）用于晚期/转移性实体瘤治疗的1期临床试验已获得相关人类研究伦理委员会的批准，并通过澳大利亚药品管理局的临床试验备案。　　HLX48是一款靶向c-MET和EGFR的双特异性抗体偶联药物，旨在通过诱导受体介导的内吞作用来实现肿瘤细胞的靶向治疗，并具备良好的安全性。市场上尚无靶向EGFR和c-MET的双特异性抗体偶联药物获得批准，公司在这一领域的开发具有潜在的市场机会。（文章来源：财中社）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2635200887","isCrawlerRequest":true}

复宏汉霖： HLX48获澳洲临床备案 填补同类药物市场空白

精彩评论

复宏汉霖： HLX48获澳洲临床备案填补同类药物市场空白